```html

Lichenoid Drug Reaction (LDR)

Overview

A lichenoid drug reaction (LDR) is an adverse cutaneous eruption that mimics the appearance of lichen planus but is triggered by a medication. The rash typically appears as violaceous, flat‑topped papules that may coalesce into plaques and can involve the skin, oral mucosa, genital mucosa, or nails.

Who it affects: LDR can occur in adults of any age but is most common in middle‑aged to older adults (median age ≈ 55 years). Women appear to be slightly more likely to develop the reaction, possibly because they take a higher number of prescription medications.

Prevalence: Exact incidence is unknown because LDR is often under‑reported, but drug‑induced lichenoid eruptions account for about 10–20 % of all lichenoid skin diseases reported in dermatology clinics (Mayo Clinic, 2023). Certain high‑risk drugs (e.g., antihypertensives, antimalarials, checkpoint inhibitors) increase the odds by up to 4‑fold.

Symptoms

Symptoms usually develop 1 week to 6 months after starting the offending medication, though delayed onset (up to 12 months) is possible. The presentation can be limited to the skin or involve mucosal surfaces.

Cutaneous (skin) findings

• Violaceous, flat‑topped papules – the classic “lichen planus‑like” lesions.
• Polygonal shape – often irregular, with well‑defined borders.
• Distribution – commonly on the wrists, forearms, trunk, and lower legs; may be symmetric.
• Koebner phenomenon – new lesions appear at sites of trauma (e.g., scratching).
• Pruritus – itching ranges from mild to severe.
• Erythema or hyperpigmentation – lesions may be redder in darker skin tones or become darker after healing.

Mucosal involvement

• Oral cavity – white, reticulated (Wickham’s striae) patches, painful erosions, or ulcerations on the buccal mucosa, tongue, and gingiva.
• Genital mucosa – erythematous plaques, erosions, or fissuring that can cause pain during intercourse.
• Nails – longitudinal ridging, onycholysis, or pterygium formation.

Systemic symptoms (less common)

• Low‑grade fever
• Generalized malaise
• Rarely, eosinophilia in blood work (suggesting a drug hypersensitivity component)

Causes and Risk Factors

Medications most frequently implicated

• Antihypertensives: ACE inhibitors (e.g., enalapril), thiazide diuretics, beta‑blockers.
• Antimalarials: Hydroxychloroquine, chloroquine (common in patients with rheumatoid arthritis or lupus).
• Non‑steroidal anti‑inflammatory drugs (NSAIDs): Ibuprofen, naproxen.
• Antibiotics: Tetracyclines, sulfonamides, fluoroquinolones.
• Antiretrovirals: Zidovudine, efavirenz.
• Immunotherapy agents: Checkpoint inhibitors (nivolumab, pembrolizumab) and BRAF inhibitors.
• Other drugs: Gold salts, oral hypoglycemics (sulfonylureas), antiepileptics (carbamazepine).

Risk factors

• Polypharmacy – taking three or more prescription drugs simultaneously raises risk.
• Genetic predisposition – certain HLA types (e.g., HLA‑B*57:01) have been linked to drug‑induced lichenoid eruptions.
• Pre‑existing skin conditions – patients with psoriasis or atopic dermatitis may be more sensitive.
• Age > 50 years – slower drug metabolism can increase exposure of the skin to reactive metabolites.
• Female sex – likely related to higher medication usage patterns.

Diagnosis

Diagnosing LDR is primarily clinical, but a combination of history, physical exam, and targeted investigations helps differentiate it from idiopathic lichen planus, psoriasis, or other drug eruptions.

Step‑by‑step approach

1. Medication review – document all current and recent (past 6 months) prescription, over‑the‑counter, and herbal products.
2. Timeline correlation – assess latency between drug initiation and rash onset (typically 1 week–6 months).
3. Physical examination – note morphology, distribution, and presence of mucosal lesions.
4. Skin biopsy – 4‑mm punch biopsy of an active papule is the gold standard.
5. Laboratory tests (optional) –
   • Complete blood count (CBC) – look for eosinophilia.
   • Liver & renal panels – to assess organ function before drug withdrawal.
   • Serology for hepatitis C or HIV – sometimes ordered to rule out secondary causes.

Biopsy findings

Histopathology typically shows a dense, band‑like lymphocytic infiltrate at the dermal‑epidermal junction, basal cell degeneration, saw‑tooth rete ridges, and occasional eosinophils – features that overlap with lichen planus but are more likely to include eosinophils and deeper infiltrates in drug‑induced cases.

References: Cleveland Clinic, NIH Journal of Dermatology 2022.

Treatment Options

The cornerstone of therapy is identifying and discontinuing the offending drug. Symptomatic management and, in persistent cases, immunomodulatory therapy are added.

1. Drug discontinuation

• Stop the suspected medication under physician guidance.
• Switch to an alternative class when possible (e.g., replace a thiazide diuretic with a calcium‑channel blocker).
• Improvement is usually seen within 2–4 weeks; full resolution may take 3–6 months.

2. Topical therapies

• High‑potency corticosteroids (clobetasol 0.05 % ointment) applied twice daily for 2–4 weeks.
• Calcineurin inhibitors (tacrolimus 0.1 % ointment) for sensitive areas (face, intertriginous zones) or where steroids are contraindicated.
• For oral lesions, topical dexamethasone suspension or “swish‑and‑spit” rinses.

3. Systemic therapies (for extensive or refractory disease)

• Prednisone – 0.5 mg/kg/day tapering over 4–6 weeks; effective for severe pruritus or widespread eruptions.
• Acitretin (oral retinoid) – 25‑35 mg/day; useful for hyperkeratotic lesions.
• Antihistamines – non‑sedating agents (cetirizine, loratadine) for itch control.
• Immunosuppressants – azathioprine or mycophenolate mofetil in rare chronic cases, guided by a dermatologist.

4. Phototherapy

Narrow‑band UVB can be considered when lesions are extensive and topical/systemic options are contraindicated. Sessions are usually 2–3 times per week for 12–16 weeks.

5. Lifestyle & supportive measures

• Cool compresses to relieve itching.
• Gentle skin care – fragrance‑free moisturizers, lukewarm baths.
• Avoiding scratching to prevent Koebnerization.

Living with Lichenoid Drug Reaction

Daily management tips

• Skin care routine – use mild, soap‑free cleansers and apply a thick, hypoallergenic moisturizer within 5 minutes of bathing.
• Itch control – keep fingernails trimmed; consider nighttime antihistamines.
• Sun protection – broad‑spectrum sunscreen SPF 30+ to prevent hyperpigmentation.
• Oral hygiene – soft‑bristled toothbrush, alcohol‑free mouthwash, and regular dental check‑ups if oral lesions are present.
• Medication diary – note any new drugs, dosage changes, or over‑the‑counter products; share with all healthcare providers.
• Follow‑up schedule – dermatology visits every 4–6 weeks until lesions clear, then every 6–12 months.

Psychosocial considerations

Visible lesions can affect self‑esteem. Encourage patients to seek support groups, counseling, or mental‑health referrals if anxiety or depression develops.

Prevention

• Medication vigilance – before starting a new drug, discuss known lichenoid risk with the prescriber, especially if you have a history of drug eruptions.
• Gradual dose escalation – some agents (e.g., antimalarials) are started at low doses and titrated, which may reduce risk.
• Allergy testing – patch testing can identify culprit agents in recurrent cases, but is not routinely performed.
• Regular review of drug list – annual medication reconciliation by a pharmacist or physician.

Complications

If the offending drug is not withdrawn or the reaction is inadequately treated, the following complications may arise:

• Persistent hyperpigmentation – especially on darker skin tones, which may be cosmetically distressing.
• Scarring or atrophic changes – from chronic inflammation or excoriation.
• Secondary infection – due to skin barrier disruption; may require antibiotics.
• Oral discomfort – leading to dysphagia, nutritional deficiency, or weight loss.
• Progression to generalized lichenoid eruption – rare but can mimic severe lichen planus with extensive mucosal involvement.
• Quality‑of‑life impact – chronic itching and visible lesions can cause sleep disturbance and psychological distress.

When to Seek Emergency Care

---

Sources: Mayo Clinic. Lichenoid drug eruption. 2023; CDC. Drug safety and adverse reactions. 2022; National Institutes of Health. Dermatology literature review. 2022; Cleveland Clinic. Cutaneous drug reactions. 2023; World Health Organization. Pharmacovigilance guidelines. 2021.

```